Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Monday that its US partner Ollin Biosciences has reported final, 20-week study completion data from its randomised, head-to-head Phase 1b JADE clinical study comparing OLN324 (Innovent R&D code IBI324), a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo), in patients with diabetic macular oedema (DME) or wet (neovascular) age-related macular degeneration (wAMD).

Results include favourable durability data for OLN324 compared to faricimab, and new anatomic data showing faster, greater, and more durable control of wAMD pigment epithelial detachments (PEDs) with OLN324.

Topline data from the Week 12 primary endpoint readout, previously announced in January 2026 and presented at the Angiogenesis, Exudation, and Degeneration Symposium in February 2026, demonstrated that OLN324, compared to faricimab, delivered superior anatomic outcomes in DME, including faster and greater retinal drying and more patients achieving absence of DME; equivalent retinal drying compared to faricimab in wAMD; and rapid and sustained gains in vision in both DME and wAMD that were numerically better than faricimab. It had a favourable safety profile with no cases of intraocular inflammation.

For the JADE trial, which enrolled 164 US patients with either DME or wAMD, all patients initially received three monthly doses of OLN324 or faricimab. Thereafter, they were followed for an additional 12 weeks off treatment, during which they could be retreated based on protocol-specified criteria for disease recurrence that were the same for all groups.